Dicerna Pharmaceuticals, Inc. Email Format

Pharmaceutical ManufacturingMassachusetts, United States51-200 Employees

Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing RNA interference-based therapies that aim to selectively silence disease-causing genes. It operates as a wholly owned subsidiary of Novo Nordisk and is based in Lexington, Massachusetts. The firm pursues treatments for both rare and more prevalent diseases, initially targeting genes active in the liver and expanding to other tissues through an evolved RNAi program.

A team with expertise spanning biology, chemistry, clinical science, and medicine supports its research and development, drawing on decades of RNAi experience. The company maintains a pipeline that includes internal discovery and clinical candidates as well as collaborative programs with other major pharmaceutical companies, totaling more than 20 active discovery, preclinical, or clinical efforts across rare, cardiometabolic, viral, chronic liver, complement-mediated diseases, neurodegenerative conditions, and pain.

Get verified Dicerna Pharmaceuticals, Inc. emails free

Company overview Employee directory